{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:55:13Z","timestamp":1794743713289,"version":"4.9.1"},"reference-count":26,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Avalyn Pharma","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2023,1,13]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Oral pirfenidone reduces lung function decline and mortality in patients with idiopathic pulmonary fibrosis (IPF). Systemic exposure can have significant side effects, including nausea, rash, photosensitivity, weight loss and fatigue. Reduced doses may be suboptimal in slowing disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase 1b, randomised, open-label, dose\u2013response trial at 25 sites in six countries (Australian New Zealand Clinical Trials Registry (ANZCTR) registration number ACTRN12618001838202) assessed safety, tolerability and efficacy of inhaled pirfenidone (AP01) in IPF. Patients diagnosed within 5 years, with forced vital capacity (FVC) 40%\u201390% predicted, and intolerant, unwilling or ineligible for oral pirfenidone or nintedanib were randomly assigned 1:1 to nebulised AP01 50 mg once per day or 100 mg two times per day for up to 72 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We present results for week 24, the primary endpoint and week 48 for comparability with published trials of antifibrotics. Week 72 data will be reported as a separate analysis pooled with the ongoing open-label extension study. Ninety-one patients (50 mg once per day: n=46, 100 mg two times per day: n=45) were enrolled from May 2019 to April 2020. The most common treatment-related adverse events (frequency, % of patients) were all mild or moderate and included cough (14, 15.4%), rash (11, 12.1%), nausea (8, 8.8%), throat irritation (5, 5.5%), fatigue (4, 4.4%) and taste disorder, dizziness and dyspnoea (three each, 3.3%). Changes in FVC % predicted over 24 and 48 weeks, respectively, were \u22122.5 (95% CI \u22125.3 to 0.4, \u221288 mL) and \u22124.9 (\u22127.5 to \u22122.3,\u2013188 mL) in the 50 mg once per day and 0.6 (\u22122.2 to 3.4, 10 mL) and \u22120.4 (\u22123.2 to 2.3, \u221234 mL) in the 100 mg two times per day group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Side effects commonly associated with oral pirfenidone in other clinical trials were less frequent with AP01. Mean FVC % predicted remained stable in the 100 mg two times per day group. Further study of AP01 is warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ACTRN12618001838202 Australian New Zealand Clinical Trials Registry.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/thorax-2022-219391","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T13:25:16Z","timestamp":1679491516000},"page":"882-889","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":70,"title":["Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose\u2013response trial"],"prefix":"10.1136","volume":"78","author":[{"given":"Alex","family":"West","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazia","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Barczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret L","family":"Wilsher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Glaspole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamera Jo","family":"Corte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"\u0160terclov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Veale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Jassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies S","family":"Wijsenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Grainge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Piotrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Raghu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele L","family":"Shaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepthi","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Bruce","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"key":"2024051320333806000_78.9.882.1","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-017-0621-y","article-title":"Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry","volume":"18","author":"Kreuter","year":"2017","journal-title":"Respir Res"},{"key":"2024051320333806000_78.9.882.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30866-8"},{"key":"2024051320333806000_78.9.882.3","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.2.ats3-00"},{"key":"2024051320333806000_78.9.882.4","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S2213-2600(14)70101-8","article-title":"Idiopathic pulmonary fibrosis in US medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11","volume":"2","author":"Raghu","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2024051320333806000_78.9.882.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2024051320333806000_78.9.882.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"2024051320333806000_78.9.882.7","unstructured":"Boehringer Ingelheim Pharmaceuticals . OFEV\u00ae (nintedanib) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals,"},{"key":"2024051320333806000_78.9.882.8","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2015-000105","article-title":"Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials","volume":"3","author":"Lancaster","year":"2016","journal-title":"BMJ Open Respir Res"},{"key":"2024051320333806000_78.9.882.9","article-title":"Pirfenidone and nintedanib compliance and persistence in A real world setting","volume":"195","author":"Lalla","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024051320333806000_78.9.882.10","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-021-01714-y","article-title":"Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis","volume":"22","author":"Belhassen","year":"2021","journal-title":"Respir Res"},{"key":"2024051320333806000_78.9.882.11","doi-asserted-by":"publisher","DOI":"10.1136\/thx.39.1.1"},{"key":"2024051320333806000_78.9.882.12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/jamp.2018.1507","article-title":"A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 study of aerosolized pirfenidone delivered via the PARI investigational eflow nebulizer in volunteers and patients with idiopathic pulmonary fibrosis","volume":"33","author":"Khoo","year":"2020","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"2024051320333806000_78.9.882.13","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00034805"},{"key":"2024051320333806000_78.9.882.14","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.4.339"},{"key":"2024051320333806000_78.9.882.15","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-201581"},{"key":"2024051320333806000_78.9.882.16","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00057407"},{"key":"2024051320333806000_78.9.882.17","first-page":"S26","article-title":"A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients","volume":"28","author":"Kim","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2024051320333806000_78.9.882.18","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00080312"},{"key":"2024051320333806000_78.9.882.19","doi-asserted-by":"crossref","unstructured":"Stanojevic S , Graham B , Cooper B , et al . Official ERS technical standards: global lung function initiative reference values for the carbon monoxide transfer factor for caucasians. Eur Respir J 2020;56. doi:10.1183\/13993003.50010-2017","DOI":"10.1183\/13993003.50010-2017"},{"key":"2024051320333806000_78.9.882.20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2018.12.158","article-title":"Defining minimal clinically important differences (MCID) on the Leicester cough questionnaire (LCQ): analyses of a phase 2 randomized controlled trial in chronic cough","volume":"143","author":"Birring","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"2024051320333806000_78.9.882.21","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"2024051320333806000_78.9.882.22","unstructured":"Genentech USA Inc . Prescribing information for ESBRIET\u00ae (pirfenidone) capsules and film-coated tablets, for oral use. 2016. Available: https:\/\/www.gene.com\/download\/pdf\/esbriet_prescribing.pdf"},{"key":"2024051320333806000_78.9.882.23","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0057-2017","article-title":"Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis","volume":"26","author":"Lancaster","year":"2017","journal-title":"Eur Respir Rev"},{"key":"2024051320333806000_78.9.882.24","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01157-2017","article-title":"Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis","volume":"50","author":"van Manen","year":"2017","journal-title":"Eur Respir J"},{"key":"2024051320333806000_78.9.882.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2018-000363","article-title":"The King\u2019s brief interstitial lung disease (KBILD) questionnaire: an updated minimal clinically important difference","volume":"6","author":"Sinha","year":"2019","journal-title":"BMJ Open Respir Res"},{"key":"2024051320333806000_78.9.882.26","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-019-2732-2","article-title":"Aerosol pirfenidone pharmacokinetics after inhaled delivery in sheep: a viable approach to treating idiopathic pulmonary fibrosis","volume":"37","author":"Kaminskas","year":"2019","journal-title":"Pharm Res"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2022-219391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T23:50:11Z","timestamp":1715644211000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2022-219391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,8,16]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/thorax-2022-219391"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2022-219391","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,22]]}}}